Literature DB >> 22314936

A pragmatic randomised controlled trial of the effectiveness and cost-effectiveness of screening older women for the prevention of fractures: rationale, design and methods for the SCOOP study.

L Shepstone1, R Fordham, E Lenaghan, I Harvey, C Cooper, N Gittoes, A Heawood, T J Peters, T O'Neill, D Torgerson, R Holland, A Howe, T Marshall, J A Kanis, E McCloskey.   

Abstract

SCOOP is a UK seven-centre, pragmatic, randomised controlled trial with 5-year follow-up, including 11,580 women aged 70 to 85 years, to assess the effectiveness and cost-effectiveness of a community-based screening programme to reduce fractures. It utilises the FRAX algorithm and DXA to assess the 10-year probability of fracture. Introduction Osteoporotic, or low-trauma, fractures present a considerable burden to the National Health Service and have major adverse effects on quality of life, disability and mortality for the individual. Methods Given the availability of efficacious treatments and a risk assessment tool based upon clinical risk factors and bone mineral density, a case exists to undertake a community-based controlled evaluation of screening for subjects at high risk of fracture, under the hypothesis that such a screening programme would reduce fractures in this population. Results This study is a UK seven-centre, unblinded, pragmatic, randomised controlled trial with a 5-year follow-up period. A total of 11,580 women, aged 70 to 85 years and not on prescribed bone protective therapy will be consented to the trial by post via primary care providing 90% power to detect an 18% decrease in fractures. Conclusions Participants will be randomised to either a screening arm or control. Those undergoing screening will have a 10-year fracture probability computed from baseline risk factors together with bone mineral density measured by DXA in selected subjects. Individuals above an age-dependent threshold of fracture probability will be recommended for treatment for the duration of the trial. Subjects in the control arm will receive 'usual care'. Participants will be followed up 6 months after randomisation and annually by postal questionnaires with independent checking of hospital and primary care records. The primary outcome will be the proportion of individuals sustaining fractures in each group. An economic analysis will be carried out to assess cost-effectiveness of screening. A qualitative evaluation will be conducted to examine the acceptability of the process to participants.

Entities:  

Mesh:

Year:  2012        PMID: 22314936     DOI: 10.1007/s00198-011-1876-7

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN: 0937-941X            Impact factor:   4.507


  37 in total

Review 1.  Treatment of established osteoporosis: a systematic review and cost-utility analysis.

Authors:  J A Kanis; J E Brazier; M Stevenson; N W Calvert; M Lloyd Jones
Journal:  Health Technol Assess       Date:  2002       Impact factor: 4.014

Review 2.  Assessment of fracture risk.

Authors:  John A Kanis; Frederik Borgstrom; Chris De Laet; Helena Johansson; Olof Johnell; Bengt Jonsson; Anders Oden; Niklas Zethraeus; Bruce Pfleger; Nikolai Khaltaev
Journal:  Osteoporos Int       Date:  2004-12-23       Impact factor: 4.507

3.  Epidemiology of fractures in England and Wales.

Authors:  T P van Staa; E M Dennison; H G Leufkens; C Cooper
Journal:  Bone       Date:  2001-12       Impact factor: 4.398

4.  Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group.

Authors:  M R McClung; P Geusens; P D Miller; H Zippel; W G Bensen; C Roux; S Adami; I Fogelman; T Diamond; R Eastell; P J Meunier; J Y Reginster
Journal:  N Engl J Med       Date:  2001-02-01       Impact factor: 91.245

5.  Effect of raloxifene on the risk of new vertebral fracture in postmenopausal women with osteopenia or osteoporosis: a reanalysis of the Multiple Outcomes of Raloxifene Evaluation trial.

Authors:  John A Kanis; Olof Johnell; Dennis M Black; Robert W Downs; Somnath Sarkar; Thomas Fuerst; Roberta J Secrest; Imre Pavo
Journal:  Bone       Date:  2003-09       Impact factor: 4.398

6.  Fracture incidence and association with bone mineral density in elderly men and women: the Rotterdam Study.

Authors:  S C E Schuit; M van der Klift; A E A M Weel; C E D H de Laet; H Burger; E Seeman; A Hofman; A G Uitterlinden; J P T M van Leeuwen; H A P Pols
Journal:  Bone       Date:  2004-01       Impact factor: 4.398

7.  Clodronate reduces vertebral fracture risk in women with postmenopausal or secondary osteoporosis: results of a double-blind, placebo-controlled 3-year study.

Authors:  Eugene McCloskey; Peter Selby; Mike Davies; John Robinson; Roger M Francis; Judith Adams; Karthik Kayan; Monique Beneton; Tarja Jalava; Liisa Pylkkänen; Juha Kenraali; Sakari Aropuu; John A Kanis
Journal:  J Bone Miner Res       Date:  2004-01-19       Impact factor: 6.741

8.  Utility of medical and drug history in fracture risk prediction among men and women.

Authors:  T P van Staa; H G M Leufkens; C Cooper
Journal:  Bone       Date:  2002-10       Impact factor: 4.398

9.  Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures.

Authors:  D Marshall; O Johnell; H Wedel
Journal:  BMJ       Date:  1996-05-18

Review 10.  The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women.

Authors:  J A Kanis; A Oden; O Johnell; H Johansson; C De Laet; J Brown; P Burckhardt; C Cooper; C Christiansen; S Cummings; J A Eisman; S Fujiwara; C Glüer; D Goltzman; D Hans; M-A Krieg; A La Croix; E McCloskey; D Mellstrom; L J Melton; H Pols; J Reeve; K Sanders; A-M Schott; A Silman; D Torgerson; T van Staa; N B Watts; N Yoshimura
Journal:  Osteoporos Int       Date:  2007-02-24       Impact factor: 4.507

View more
  24 in total

1.  Access to fracture risk assessment by FRAX and linked National Osteoporosis Guideline Group (NOGG) guidance in the UK-an analysis of anonymous website activity.

Authors:  E V McCloskey; H Johansson; N C Harvey; J Compston; J A Kanis
Journal:  Osteoporos Int       Date:  2016-07-20       Impact factor: 4.507

2.  Systematic screening using FRAX® leads to increased use of, and adherence to, anti-osteoporosis medications: an analysis of the UK SCOOP trial.

Authors:  C M Parsons; N Harvey; L Shepstone; J A Kanis; E Lenaghan; S Clarke; R Fordham; N Gittoes; I Harvey; R Holland; N M Redmond; A Howe; T Marshall; T J Peters; D Torgerson; T W O'Neill; E McCloskey; C Cooper
Journal:  Osteoporos Int       Date:  2019-10-12       Impact factor: 4.507

3.  Geographic variation in secondary fracture prevention after a hip fracture during 1999-2013: a UK study.

Authors:  A Shah; D Prieto-Alhambra; S Hawley; A Delmestri; J Lippett; C Cooper; A Judge; M K Javaid
Journal:  Osteoporos Int       Date:  2016-11-03       Impact factor: 4.507

4.  Fracture risk assessment: state of the art, methodologically unsound, or poorly reported?

Authors:  Gary S Collins; Karl Michaëlsson
Journal:  Curr Osteoporos Rep       Date:  2012-09       Impact factor: 5.096

Review 5.  Effectiveness of interventions to improve the detection and treatment of osteoporosis in primary care settings: a systematic review and meta-analysis.

Authors:  M-C Laliberté; S Perreault; G Jouini; B J Shea; L Lalonde
Journal:  Osteoporos Int       Date:  2011-02-19       Impact factor: 4.507

6.  Bone mineral density (BMD) and vertebral trabecular bone score (TBS) for the identification of elderly women at high risk for fracture: the SEMOF cohort study.

Authors:  Albrecht W Popp; Salome Meer; Marc-Antoine Krieg; Romain Perrelet; Didier Hans; Kurt Lippuner
Journal:  Eur Spine J       Date:  2015-05-27       Impact factor: 3.134

Review 7.  A systematic review of intervention thresholds based on FRAX : A report prepared for the National Osteoporosis Guideline Group and the International Osteoporosis Foundation.

Authors:  John A Kanis; Nicholas C Harvey; Cyrus Cooper; Helena Johansson; Anders Odén; Eugene V McCloskey
Journal:  Arch Osteoporos       Date:  2016-07-27       Impact factor: 2.617

8.  Screening for high hip fracture risk does not impact on falls risk: a post hoc analysis from the SCOOP study.

Authors:  C I Condurache; S Chiu; P Chotiyarnwong; H Johansson; L Shepstone; E Lenaghan; C Cooper; S Clarke; R F S Khioe; R Fordham; N Gittoes; I Harvey; N C Harvey; A Heawood; R Holland; A Howe; J A Kanis; T Marshall; T W O'Neill; T J Peters; N M Redmond; D Torgerson; D Turner; E McCloskey
Journal:  Osteoporos Int       Date:  2020-01-20       Impact factor: 4.507

9.  The Cost-Effectiveness of Screening in the Community to Reduce Osteoporotic Fractures in Older Women in the UK: Economic Evaluation of the SCOOP Study.

Authors:  David A Turner; Rebekah Fong Soe Khioe; Lee Shepstone; Elizabeth Lenaghan; Cyrus Cooper; Neil Gittoes; Nicholas C Harvey; Richard Holland; Amanda Howe; Eugene McCloskey; Terence W O'Neill; David Torgerson; Richard Fordham
Journal:  J Bone Miner Res       Date:  2018-02-22       Impact factor: 6.741

Review 10.  Fracture prediction, imaging and screening in osteoporosis.

Authors:  Nicholas R Fuggle; Elizabeth M Curtis; Kate A Ward; Nicholas C Harvey; Elaine M Dennison; Cyrus Cooper
Journal:  Nat Rev Endocrinol       Date:  2019-09       Impact factor: 43.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.